Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECT Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3
NCT04277338Phase 1Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of [99mTc]Tc-(HE)3-G3 in breast cancer (3 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: Gamma camera-based whole-body 99mTc-HE3-G3 uptake value at 6 hours, SPECT-based 99mTc-HE3-G3 uptake value in tumor lesions at 6 hours and 2 more. Started Feb 2020; status: completed.
02
Drugs
[99mTc]Tc-(HE)3-G3
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04277338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277338.